• NORD’s Advice on COVID-19: You’re Stronger Than You Think
  • Phase 2 Trial to Test Cannabidiol-derived EHP-101 in Diffuse Cutaneous Scleroderma
  • Canada Clears EHP-101, Possible Cannabidiol-derived Treatment
  • NORD Partners with ‘Sing Me a Story’ for July 18–20 Living Rare Forum
  • Global Rare Disease Group’s Focus: 1,000 New Therapies by 2027, Despite COVID-19
  • Subset of Immune B-Cells Linked to Vascular Damage in Some Patients, Study Suggests
  • Vitamin E, Pentoxifylline and TheraBite System Ease Lockjaw, Small Study Suggests
  • Emerald Health Awarded 6 Patents for Potential Cannabis Treatments
  • Blood Levels of Fibrotic Protein Tied to SSc-ILD, May Serve as Biomarker
  • Heart, Kidney Imaging Could Detect Fibrosis in Scleroderma, Study Finds
  • New Ultrasound Technique Detects Early Skin Changes in Scleroderma, Study Suggests
  • Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds